{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:02Z","timestamp":1789450442127,"version":"build-2803163510"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004077","name":"Kocaeli University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.seizure.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T12:41:59Z","timestamp":1738845719000},"page":"95-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Apparent efficacy of NMDAR antagonist use as a targeted therapy for status epilepticus in an infant with ATP1A2-related developmental epileptic encephalopathy"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-8358","authenticated-orcid":false,"given":"Leman Tekin","family":"Orgun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-3787","authenticated-orcid":false,"given":"Adnan","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayfer Sakarya","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9297-8222","authenticated-orcid":false,"given":"Deniz","family":"Akkoyunlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6k\u00e7e","family":"C\u0131rd\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-4514","authenticated-orcid":false,"given":"An\u0131l","family":"G\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.seizure.2025.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/brain\/awab052","article-title":"ATP1A2- and ATP1A3-associated early profound epileptic encephalopathy and polymicrogyria","volume":"144","author":"Vetro","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2025.02.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107732","article-title":"Early onset severe ATP1A2 epileptic encephalopathy: clinical characteristics and underlying mutations","volume":"116","author":"Moya-Mendez","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2025.02.002_bib0003","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/epd2.20220","article-title":"ATP1A2-related epileptic encephalopathy and movement disorder: clinical features of three novel patients","volume":"26","author":"Cordoba","year":"2024","journal-title":"Epileptic Disord"},{"issue":"Suppl 5","key":"10.1016\/j.seizure.2025.02.002_bib0004","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1542\/peds.2017-0852","article-title":"Clinical benefit of NMDA receptor antagonists in a patient with ATP1A2 gene mutation","volume":"141","author":"Ueda","year":"2018","journal-title":"Pediatrics"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:40:47Z","timestamp":1772469647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125000330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":4,"alternative-id":["S1059131125000330"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.02.002","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apparent efficacy of NMDAR antagonist use as a targeted therapy for status epilepticus in an infant with ATP1A2-related developmental epileptic encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}